Abstract | BACKGROUND: METHODS: To assess the safety and efficacy profile of pertuzumab, we searched PubMed and Embase (articles from January 1966 to January 2015) using the keyword " pertuzumab". RESULTS: Fourteen eligible studies were included in our final analysis. From the results of our analysis, diarrhea (56.9%, 95% confidence interval [CI] 49.6%-63.9%), nausea (34.0%, 95% CI 27.7%-40.8%), and rash (25.6%, 95% CI 20.8%-31.0%) were the most common adverse effects in pertuzumab alone and pertuzumab-based therapies. Based on randomized controlled clinical trials, diarrhea (odds ratio [OR] 2.310, 95% CI 1.818-2.936), rash (OR 1.848, 95% CI 1.094-3.122), and febrile neutropenia (OR 1.672, 95% CI 1.130-2.474) were of statistical significance, which meant that pertuzumab played a prominent role in the incidence of diarrhea. Meanwhile, pertuzumab showed its effective role in cancer control and lifetime prolongation. CONCLUSION: In conclusion, considering that the common adverse effects for pertuzumab are gastrointestinal and skin toxicities, which are easier to handle than other toxicities, pertuzumab is a safe and effective drug for patients with solid tumors.
|
Authors | Chenjing Zhu, Wenwu Ling, Jing Zhang, Hui Gao, Kai Shen, Xuelei Ma |
Journal | Medicine
(Medicine (Baltimore))
Vol. 96
Issue 20
Pg. e6870
(May 2017)
ISSN: 1536-5964 [Electronic] United States |
PMID | 28514302
(Publication Type: Journal Article, Meta-Analysis, Review)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- pertuzumab
|
Topics |
- Antibodies, Monoclonal, Humanized
(adverse effects, therapeutic use)
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Humans
- Neoplasms
(drug therapy)
- Randomized Controlled Trials as Topic
|